Incyte Corporation (INCY)
Incyte Q2 Earnings Call Highlights
Incyte NASDAQ: INCY reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a year earlier, supported by demand growth across its marketed portfolio and a one-time non-cash benefit tied to the resolution of a CMS matter involving OPZELURA.
Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)
Incyte Corporation ends the first half of 2026 on a high note. Yesterday, its stock reached a 52-week high of $120.70. In my view, key drivers behind Incyte's recent rally are the promising efficacy of latarcibart in von Willebrand disease, along with strong performance from Opzelura and Zynyz.
Incyte (INCY) Q2 Earnings and Revenues Top Estimates
Incyte (INCY) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $1.57 per share a year ago.
Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner?
INCY heads into Q2 earnings with strong Jakafi demand, Opzelura momentum and rising royalties, fueling expectations for an earnings beat.
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Incyte: New Catalysts Support Another Leg Higher
Incyte Corporation remains a strong long pick, with a maintained 'Buy' rating and a 40% upside to a $159.5/share price target. Recent catalysts include a positive CHMP opinion for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding INCY's product portfolio and reducing Jakafi concentration risk. Q1 2026 results showed robust diversification: revenues up 21% YoY, adjusted EPS up 56% YoY, and ex-Jakafi sales up 63% YoY.
Why Incyte (INCY) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Incyte (INCY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Incyte: I Am Moving From Hold To Buy
Incyte is upgraded to Buy as pipeline progress and improved EPS estimates offset Jakafi concentration risk. frontMIND Phase 3 data for Monjuvi in first-line DLBCL is promising, supporting potential market share gains despite emerging competition. INCY acquired Vega Therapeutics, adding VGA039 to its hematology portfolio.
Incyte to Buy Vega Therapeutics in Hematology Deal Worth Up to $2B
Incyte will acquire Vega Therapeutics for up to $2B, adding late-stage VWD candidate VGA039 and expanding its hematology growth prospects.
